Bris­tol My­ers scores ac­cel­er­at­ed ap­proval in more blood can­cers for CAR-T ther­a­py Breyanzi

Bris­tol My­ers Squibb is bring­ing its CAR-T cell ther­a­py to adults with re­lapsed or re­frac­to­ry chron­ic lym­pho­cyt­ic leukemia or small lym­pho­cyt­ic lym­phoma, thanks to an ac­cel­er­at­ed ap­proval from the FDA on Thurs­day.

The one-time in­fu­sion, mar­ket­ed as Breyanzi, is al­ready ap­proved in the US, Japan and Eu­rope for the sec­ond-line treat­ment of re­lapsed or re­frac­to­ry large B-cell lym­phoma, and in Japan, Eu­rope and Cana­da for re­lapsed and re­frac­to­ry large B-cell lym­phoma in the third-line set­ting. This lat­est ex­pan­sion is for pa­tients who have re­ceived at least two pri­or lines of ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER